A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
Published version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis. Here we show a mRNA-LNP vaccine (MIT-T-COVID) based on highly conserved short peptide epitopes activates CD8 + and CD4 + T cell responses that attenuate morbidity and prevent mortality in HLA-A*02:01 transgenic mice infected with SARS-CoV-2 Beta (B.1.351). We found CD8 + T cells in mice immunized with MIT-T-COVID vaccine significantly increased from 1.1% to 24.0% of total pulmonary nucleated cells prior to and at 7 days post infection (dpi), respectively, indicating dynamic recruitment of circulating specific T cells into the infected lungs. Mice immunized with MIT-T-COVID had 2.8 (2 dpi) and 3.3 (7 dpi) times more lung infiltrating CD8 + T cells than unimmunized mice. Mice immunized with MIT-T-COVID had 17.4 times more lung infiltrating CD4 + T cells than unimmunized mice (7 dpi). The undetectable specific antibody response in MIT-T-COVID-immunized mice demonstrates specific T cell responses alone can effectively attenuate the pathogenesis of SARS-CoV-2 infection. Our results suggest further study is merited for pan-variant T cell vaccines, including for individuals that cannot produce neutralizing antibodies or to help mitigate Long COVID.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst antibody-mediated immune responses rely on HLA class II antigen presentation to CD4+ T cells, cytotoxic CD8+ T cell responses are primed via the HLA class I antigen presentation pathway and can provide potent protection against infection by eradicating infected cells and preventing viral spreading12–15.”
From Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · cited 1×
“RNA containing lipid nanoparticles were prepared as previously described (Pardi et al., 2017).”
MethodSelf-citationSARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785
Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529 · cited 7×
“Substantial literature suggests that T cell responses are integral to the adaptive immunity to COVID-19 (Moss, 2022).”
BackgroundInfluentialAirway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
Zhao, J., Zhao, J., Mangalam, A. K., Channappanavar, R., Fett, C., Meyerholz, D. K., Agnihothram, S., Baric, R. S., David, C. S., & Perlman, S. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.006 · Cited by 496
O’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.010 · Cited by 440
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4509 · Cited by 189
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · doi:10.1101/2021.05.19.444825 · Cited by 189
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122
Self-citation
Research works printed but not linked: 32
- Walsh, 2020, Safety and immunogenicity of two RNA-based covid-19 vaccine candidates, N Engl J Med, 383, 10.1056/NEJMoa2027906 · doi:10.1056/nejmoa2027906 · Paper page
- Tregoning, 2021, Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape, Nat Rev Immunol, 21, 10.1038/s41577-021-00592-1 · DOI · Paper page
- Zhang, 2021, SARS-CoV-2 omicron strain exhibits potent capabilities for immune evasion and viral entrance, Signal Transduct Target Ther, 6, 430, 10.1038/s41392-021-00852-5 · DOI · Paper page
- Shuai, 2021, Emerging SARS-CoV-2 variants expand species tropism to murines, EBioMedicine, 73, 10.1016/j.ebiom.2021.103643 · DOI · Paper page
- Martinez, 2021, Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice, Science, 373, 10.1126/science.abi4506 · DOI · Paper page
- Cohen, 2022, Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models, Science, 377, 10.1126/science.abq0839 · DOI · Paper page
- Liu, 2020, Computationally optimized SARS-CoV-2 MHC class I and II vaccine formulations predicted to target human haplotype distributions, Cell Syst, 11, 131, 10.1016/j.cels.2020.06.009 · DOI
- Nathan, 2021, Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses, Cell, 184, 4401, 10.1016/j.cell.2021.06.029 · DOI · Paper page
- Liu, 2021, Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets, Cell Syst, 12, 102, 10.1016/j.cels.2020.11.010 · DOI
- Liu, 2022, International conference on learning representations, ICLR
- Kreiter, 2008, Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J Immunol, 180, 10.4049/jimmunol.180.1.309 · DOI · Paper page
- Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 10.1038/nature23003 · DOI · Paper page
- Vita, 2018, The immune epitope database (IEDB): 2018 update, Nucleic Acids Res, 47, 10.1093/nar/gky1006 · DOI · Paper page
- Kotturi, 2009, Of mice and humans: How good are HLA transgenic mice as a model of human immune responses, Immunome Res, 5, 10.1186/1745-7580-5-3 · DOI
- Croft, 2019, Most viral peptides displayed by class I MHC on infected cells are immunogenic, Proc Natl Acad Sci U.S.A., 116, 10.1073/pnas.1815239116 · DOI
- Nakiboneka, 2019, Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens, Vaccine, 37, 10.1016/j.vaccine.2018.11.024 · DOI
- Halfmann, 2022, SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters, Nature, 603, 10.1038/s41586-022-04441-6 · DOI · Paper page
- Kumari, 2021, Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice, Viruses, 13, 10.3390/v13010132 · DOI · Paper page
- Moss, 2022, The T cell immune response against SARS-CoV-2, Nat Immunol, 23, 10.1038/s41590-021-01122-w · DOI · Paper page
- de Silva, 2021, The impact of viral mutations on recognition by SARS-CoV-2 specific T cells, iScience, 24, 10.1016/j.isci.2021.103353 · DOI
- Redd, 2021, CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants, medRxiv, 12, 10.1101/2021.02.11.21251585 · DOI
- Benjamini, 2022, Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia, Haematologica, 107, 10.3324/haematol.2021.279196 · DOI
- Heitmann, 2022, A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity, Nature, 601, 10.1038/s41586-021-04232-5 · DOI · Paper page
- Pardieck, 2022, A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection, Nat Commun, 13, 3966, 10.1038/s41467-022-31721-6 · DOI
- Sekine, 2020, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell, 183, 158, 10.1016/j.cell.2020.08.017 · DOI · Paper page
- Shree, 2022, Shree T. Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity, Br J Haematol, 197, 659, 10.1111/bjh.18210 · DOI
- Kingstad-Bakke, 2022, Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants, Proc Natl Acad Sci U.S.A., 119, 10.1073/pnas.2118312119 · DOI
- Matchett, 2021, Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity, J Immunol, 207, 10.4049/jimmunol.2100421 · DOI · Paper page
- Ellis, 2000, Frequencies of HLA-A2 alleles in five U.S. population groups. predominance of A*02011 and identification of HLA-A*0231, Hum Immunol, 61, 10.1016/s0198-8859(99)00155-x · DOI · Paper page
- Pavord, 2021, Clinical features of vaccine-induced immune thrombocytopenia and thrombosis, N Engl J Med, 385, 10.1056/NEJMoa2109908 · DOI · Paper page
- de Oliveira, 2022, Brazillian VITT investigative collaboration group. vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil, Vaccine, 40, 10.1016/j.vaccine.2022.06.014 · DOI
- Swank, 2022, Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae, Clin Infect Dis, 76, 10.1093/cid/ciac722 · DOI · Paper page
Cited by
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51959-6 · Cited by 12
Metadata
- Authors
- Carter, B., Huang, P., Liu, G., Liang, Y., Lin, P. J. C., Peng, B.-H., McKay, L. G. A., Dimitrakakis, A., Hsu, J., Tat, V., Saenkham-Huntsinger, P., Chen, J., Kaseke, C., Gaiha, G. D., Xu, Q., Griffiths, A., Tam, Y. K., Tseng, C.-T. K., & Gifford, D. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-09
- Volume
- 14
- ISSN
- 1664-3224
- Cited by
- 10
- References
- 10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. https://app.cochat.ai/papers/10.3389/fimmu.2023.1135815
- The paper
- Carter, B., Huang, P., Liu, G., Liang, Y., Lin, P. J. C., Peng, B.-H., McKay, L. G. A., Dimitrakakis, A., Hsu, J., Tat, V., Saenkham-Huntsinger, P., Chen, J., Kaseke, C., Gaiha, G. D., Xu, Q., Griffiths, A., Tam, Y. K., Tseng, C.-T. K., & Gifford, D. K. (2023). A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1135815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.